Drug Farm candidate gains rare paediatric disease status
Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.
Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.
What's Your Reaction?
